Андрология и генитальная хирургия. 2012; 13: 4-12
Патогенетические корреляции андрогенного дефицита и уронефрологических заболеваний почек у мужчин (литературный обзор)
https://doi.org/10.17650/2070-9781-2012-4-4-12Аннотация
В литературном обзоре на основе современных эпидемиологических и клинико-экспериментальных исследований рассмотрены механизмы патофизиологического взаимодействия андрогенного дефицита, ассоциированных с ним метаболических нарушений (компонентов метаболического синдрома) и нарушений гомеостаза, обусловленных уронефрологическими заболеваниями почек у мужчин. Описаны как механизмы развития андрогенного дефицита при патологии почек, так и взаимное влияние андрогенного дефицита на анатомо-функциональное состояние почек у мужчин. В краткой форме представлена информация о механизмах и диагностико-прогностической роли гиперпролактинемии при заболеваниях почек у мужчин, а также освещены вопросы современного состояния проблемы целесообразности и возможности проведения андрогензаместительной терапии у этой категории пациентов. Заболевания почек у мужчин представляют собой сложную междисциплинарную проблему, поэтому для успешного решения современных вопросов их ранней диагностики, патогенетической терапии и профилактики требуется безусловное взаимодействие врачей различных специальностей.
Список литературы
1. Урология. Клинические рекомендации. Под ред. Н.А. Лопаткина. М.: ГЭОТАР-Медиа, 2007. 368 с.
2. Урология. Национальное руководство. Под ред. Н.А. Лопаткина. М.: ГЭОТАР-Медиа, 2009. 1024 с.
3. Ханно Ф.М., Малкович С.Б., Вейн А.Дж. Руководство по клинической урологии. Пер. с англ. под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2006. 543 с.
4. Аляев Ю.Г., Григорян В.А., Чалый М.Е. Нарушения половой и репродуктивной функции у мужчин. М.: Литтера, 2006. 188 с.
5. Верткин А.Л., Пушкарь Д.Ю. Возрастной андрогенный дефицит и эректильная дисфункция. М.: ГЭОТАР-Медиа, 2009. 176 с.
6. Калинченко С.Ю., Тюзиков И.А. Практическая андрология. М.: Практическая медицина, 2009. 400 с.
7. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care 2001;4:499–502.
8. Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic syndrome and urological diseases. Rev Urol 2010;12(4):157–80.
9. Cheng H.T., Huang J.W., Chiang C.K. et al. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J Clin Endocrinol Metab 2012;97(4):1268–76.
10. Kalyani R.R., Dobs A.S. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14:226–34.
11. Carrero J.J., Qureshi A.R., Parini P. et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009;20(3):613–20.
12. Abate N., Chandalia M., Cabo-Chan A.V. Jr. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386–92.
13. Тюзиков И.А., Иванов А.П. Новые патогенетические механизмы заболеваний единственной почки (пилотное исследование). Фундаментальные исследования 2011;11(Часть 2): 366–8.
14. Тюзиков И.А., Мартов А.Г. Системные метаболические факторы патогенеза заболеваний единственной почки у мужчин (пилотное исследование). Урология 2012;3:11–4.
15. Niemczyk S., Niemczyk L., Romejko Ciepielewska K. Basic endocrinological disorders in chronic renal failure. Endokrynol Pol 2012;63(3):250–7.
16. Iglesias P., Carrero J.J., Díez J.J. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol 2012;25(1):31–42.
17. Калинченко С.Ю., Тюзиков И.А. Метаболический синдром и уролитиаз (литературный обзор). Медицинский алфавит. Больница 2011;3:33–40.
18. Scales C.D. Jr, Curtis L.H., Norris R.D. Changing gender prevalence of stone disease. J Urol 2007;177:979–82.
19. Шустер П.И. Возрастной андрогенный дефицит – один из ведущих этиологических факторов уролитиаза у мужчин. Материалы IV Всероссийского Конгресса «Мужское здоровье». М., 2008. С. 37–8.
20. Новикова М.С., Шилов Е.М., Калинченко С.Ю. и др. Влияние гипогонадизма и его коррекции на скорость клубочковой фильтрации у мужчин с метаболическим синдромом. Материалы IV Всероссийского Конгресса «Мужское здоровье». М., 2008. С. 35–6.
21. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455–62.
22. Pérez-Torres I., Guarner V., El Hafidi M., Baños G. Sex hormones, metabolic syndrome and kidney. Curr Top Med Chem 2011;11(13):1694–705.
23. Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens 2008;17:304–9.
24. Pham H., Utzschneider K.M., de Boer I.H. Measurement of insulin resistance in chronic kidney disease. Curr Opin Nephrol Hypertens 2011;20(6):640–6.
25. Svartberg J., von Möhlen D., Schirmer H. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. Eur J Endocrinol 2004;150:65–71.
26. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002;63:1921–35.
27. Traish A.M., Saad F., Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009;30:23–32.
28. Lu Y., Fu Y., Ge Y. et al. The vasodilatory effect of testosterone on renal afferent arterioles. Gend Med 2012;9(2):103–11.
29. Yilmaz M.I., Sonmez A., Qureshi A.R. et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with non dialysis chronic kidney disease. Clin J Am Soc Nephrol 2011;6(7):1617–25.
30. Ferrucci L., Maggio M., Bandinelli S. et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006;166(13):1380–8.
31. Батюшин М.М. Нефрология. Ключи к трудному диагнозу. Элиста: ЗАО НПП «Джангар», 2009. 168 с.
32. Rodrigo R., Rivera G. Renal damage mediated by oxidative stress: a hypothesis of protective effects of red wine. Free Radical Biol Med 2002;33(3):409–22.
33. Sahovic V., Sahovic S., Grosa E. et al. Correlation between parathormone and sexual hormones in patients on haemodialysis. Med Arh 2012;66(3):177–80.
34. Stenvinkel P., Bárány P. Hypogonadism in males with chronic kidney disease: another cause of resistance to erythropoiesisstimulating agents? Contrib Nephrol 2012;178:35–9.
35. Waalen J., von Löhneysen K., Lee P. et al. Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol 2011;87(2):107–16.
36. Zitzmann M. Testosterone deficiency and treatment in older men: definition, treatment, pitfalls. Asian J Androl 2010;12(5):623–5.
37. Ali B.H., Ahmed I.H. Hormonal replacement therapy in an animal model with chronic renal failure and gonadectomy: biochemical and hematological study. Ren Fail 2006;28(4):331–5.
38. Alberti G. Introduction to the metabolic syndrome. Eur Heart J 2005;Suppl. D(7):РР3–5.
39. Huang P.L. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231–7.
40. Gustafson B., Hammarstedt А., Andersson C.X., Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2276–83.
41. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–55.
42. Sánchez-Lara K., Morales-Graf L., Green D. Cancer and obesity. Cancer Causes Control 2011;22(2):291–9.
43. Ройтберг Г.Е. Метаболический синдром. М.: МЕДпресс-информ, 2007. 224 с.
44. Lee M.J., Fried S.K. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009;296:1230–8.
45. Kapoor D., Clarke S., Stanworth R. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007;156:595–602.
46. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003;14:281–7.
47. Weinberg J.M. Lipotoxicity. Kidney Int 2006;70(9):1560–6.
48. Bobulescu I.A., Dubree M., Zhang J. Effect of renal lipid accumulation on proximal tubule Na+/H+ exchange and ammonium secretion. Am J Physiol Renal Physiol 2008;294:1315–22.
49. Kittikulsuth W., Sullivan J.C., Pollock D.M. ET-1 actions in the kidney: evidence for sex differences. Br J Pharmacol 2012;Feb 28. doi: 10.1111/j.1476-5381.2012.01922.x. [Epub ahead of print].
50. Ensling M., Steinmann W., Whaley Connell A. Hypoglycemia: a possible link between insulin resistance, metabolic dyslipidemia, and heart and kidney disease (the cardiorenal syndrome). Cardiorenal Med 2011;1(1):67–74.
51. Strazzullo P., Barba G., Vuotto P. Past history of nephrolithiasis and incidence of hypertension in men: a reappraisal based on the results of the Olivetti Prospective Heart Study. Nephrol Dial Transplant 2001;16:2232–5.
52. Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология. М.: Медицина, 2000. 631 с.
53. Калинченко С.Ю. Шаг вперед в лечении гиперпролактинемии. М.: Практическая медицина, 2010. 94 с.
54. Мельниченко Г.А., Марова Е.И., Дзеранова Л.К., Вакс В.В. Гиперпролактинемия у женщин и мужчин. М.: Эндокринологический научный центр, 2007. 53 с.
55. Crambert S., Sjöberg A., Eklöf A.C. et al. Prolactin and dopamine 1-like receptor interaction in renal proximal tubular cells. Am J Physiol Renal Physiol 2010; 299(1):49–54.
56. Niemczyk S., Matuszkiewicz-Rowińska J., Szamotulska K. et al. Circadian profile of the prolactin concentration in the patients with end-stage renal failure. Pol Arch Med Wewn 2006;116(6):1137–43.
57. Sari F., Sari R., Ozdem S. et al. Serum prolactin and macroprolactin levels in diabetic nephropathy. Clin Nephrol 2012;78(1):33–9.
58. Carrero J.J., Kyriazis J., Sonmez A. et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012;7(2):207–15.
59. Johansen K.L. Treatment of hypogonadism in men with chronic kidney disease. Adv Chronic Kidney Dis 2004;11(4):348–56.
60. Johansen K.L. Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Semin Dial 2004;17(3):202–8.
Andrology and Genital Surgery. 2012; 13: 4-12
Pathogenetic correlations androgen deficiency and uronephrological kidneys diseases at men (the literary review)
https://doi.org/10.17650/2070-9781-2012-4-4-12Abstract
Mechanisms of pathophysiological interactions of androgen deficiency, associated with it the metabolic disorders (components of a metabolic syndrome) and the homeostasis disorders caused by uronephrological kidneys diseases at men based on the modern epidemiological, clinical and experimental investigations are considered in the literary review. There are described either androgen deficiency development mechanisms in kidneys pathology or mutual androgen deficiency influence an anatomic and functional condition of kidneys at men. The information about mechanisms and diagnostics and prognostic role of hyperprolactinaemia in kidneys diseases at men is presented, and also questions of a current state of a problem of expediency and carrying out possibility androgen re-placement therapies at this patients category are covered in the short form too. Kidneys diseases at men represent as the difficult interdisciplinary problem, therefore for the successful decision of modern questions of their early diagnostics, pathogenetic therapy and prevention unconditional interaction of various medical specialties is required.
References
1. Urologiya. Klinicheskie rekomendatsii. Pod red. N.A. Lopatkina. M.: GEOTAR-Media, 2007. 368 s.
2. Urologiya. Natsional'noe rukovodstvo. Pod red. N.A. Lopatkina. M.: GEOTAR-Media, 2009. 1024 s.
3. Khanno F.M., Malkovich S.B., Vein A.Dzh. Rukovodstvo po klinicheskoi urologii. Per. s angl. pod red. Yu.G. Alyaeva. M.: GEOTAR-Media, 2006. 543 s.
4. Alyaev Yu.G., Grigoryan V.A., Chalyi M.E. Narusheniya polovoi i reproduktivnoi funktsii u muzhchin. M.: Littera, 2006. 188 s.
5. Vertkin A.L., Pushkar' D.Yu. Vozrastnoi androgennyi defitsit i erektil'naya disfunktsiya. M.: GEOTAR-Media, 2009. 176 s.
6. Kalinchenko S.Yu., Tyuzikov I.A. Prakticheskaya andrologiya. M.: Prakticheskaya meditsina, 2009. 400 s.
7. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care 2001;4:499–502.
8. Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic syndrome and urological diseases. Rev Urol 2010;12(4):157–80.
9. Cheng H.T., Huang J.W., Chiang C.K. et al. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J Clin Endocrinol Metab 2012;97(4):1268–76.
10. Kalyani R.R., Dobs A.S. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14:226–34.
11. Carrero J.J., Qureshi A.R., Parini P. et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009;20(3):613–20.
12. Abate N., Chandalia M., Cabo-Chan A.V. Jr. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386–92.
13. Tyuzikov I.A., Ivanov A.P. Novye patogeneticheskie mekhanizmy zabolevanii edinstvennoi pochki (pilotnoe issledovanie). Fundamental'nye issledovaniya 2011;11(Chast' 2): 366–8.
14. Tyuzikov I.A., Martov A.G. Sistemnye metabolicheskie faktory patogeneza zabolevanii edinstvennoi pochki u muzhchin (pilotnoe issledovanie). Urologiya 2012;3:11–4.
15. Niemczyk S., Niemczyk L., Romejko Ciepielewska K. Basic endocrinological disorders in chronic renal failure. Endokrynol Pol 2012;63(3):250–7.
16. Iglesias P., Carrero J.J., Díez J.J. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol 2012;25(1):31–42.
17. Kalinchenko S.Yu., Tyuzikov I.A. Metabolicheskii sindrom i urolitiaz (literaturnyi obzor). Meditsinskii alfavit. Bol'nitsa 2011;3:33–40.
18. Scales C.D. Jr, Curtis L.H., Norris R.D. Changing gender prevalence of stone disease. J Urol 2007;177:979–82.
19. Shuster P.I. Vozrastnoi androgennyi defitsit – odin iz vedushchikh etiologicheskikh faktorov urolitiaza u muzhchin. Materialy IV Vserossiiskogo Kongressa «Muzhskoe zdorov'e». M., 2008. S. 37–8.
20. Novikova M.S., Shilov E.M., Kalinchenko S.Yu. i dr. Vliyanie gipogonadizma i ego korrektsii na skorost' klubochkovoi fil'tratsii u muzhchin s metabolicheskim sindromom. Materialy IV Vserossiiskogo Kongressa «Muzhskoe zdorov'e». M., 2008. S. 35–6.
21. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455–62.
22. Pérez-Torres I., Guarner V., El Hafidi M., Baños G. Sex hormones, metabolic syndrome and kidney. Curr Top Med Chem 2011;11(13):1694–705.
23. Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens 2008;17:304–9.
24. Pham H., Utzschneider K.M., de Boer I.H. Measurement of insulin resistance in chronic kidney disease. Curr Opin Nephrol Hypertens 2011;20(6):640–6.
25. Svartberg J., von Möhlen D., Schirmer H. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. Eur J Endocrinol 2004;150:65–71.
26. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002;63:1921–35.
27. Traish A.M., Saad F., Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009;30:23–32.
28. Lu Y., Fu Y., Ge Y. et al. The vasodilatory effect of testosterone on renal afferent arterioles. Gend Med 2012;9(2):103–11.
29. Yilmaz M.I., Sonmez A., Qureshi A.R. et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with non dialysis chronic kidney disease. Clin J Am Soc Nephrol 2011;6(7):1617–25.
30. Ferrucci L., Maggio M., Bandinelli S. et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006;166(13):1380–8.
31. Batyushin M.M. Nefrologiya. Klyuchi k trudnomu diagnozu. Elista: ZAO NPP «Dzhangar», 2009. 168 s.
32. Rodrigo R., Rivera G. Renal damage mediated by oxidative stress: a hypothesis of protective effects of red wine. Free Radical Biol Med 2002;33(3):409–22.
33. Sahovic V., Sahovic S., Grosa E. et al. Correlation between parathormone and sexual hormones in patients on haemodialysis. Med Arh 2012;66(3):177–80.
34. Stenvinkel P., Bárány P. Hypogonadism in males with chronic kidney disease: another cause of resistance to erythropoiesisstimulating agents? Contrib Nephrol 2012;178:35–9.
35. Waalen J., von Löhneysen K., Lee P. et al. Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol 2011;87(2):107–16.
36. Zitzmann M. Testosterone deficiency and treatment in older men: definition, treatment, pitfalls. Asian J Androl 2010;12(5):623–5.
37. Ali B.H., Ahmed I.H. Hormonal replacement therapy in an animal model with chronic renal failure and gonadectomy: biochemical and hematological study. Ren Fail 2006;28(4):331–5.
38. Alberti G. Introduction to the metabolic syndrome. Eur Heart J 2005;Suppl. D(7):RR3–5.
39. Huang P.L. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231–7.
40. Gustafson B., Hammarstedt A., Andersson C.X., Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2276–83.
41. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–55.
42. Sánchez-Lara K., Morales-Graf L., Green D. Cancer and obesity. Cancer Causes Control 2011;22(2):291–9.
43. Roitberg G.E. Metabolicheskii sindrom. M.: MEDpress-inform, 2007. 224 s.
44. Lee M.J., Fried S.K. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009;296:1230–8.
45. Kapoor D., Clarke S., Stanworth R. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007;156:595–602.
46. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003;14:281–7.
47. Weinberg J.M. Lipotoxicity. Kidney Int 2006;70(9):1560–6.
48. Bobulescu I.A., Dubree M., Zhang J. Effect of renal lipid accumulation on proximal tubule Na+/H+ exchange and ammonium secretion. Am J Physiol Renal Physiol 2008;294:1315–22.
49. Kittikulsuth W., Sullivan J.C., Pollock D.M. ET-1 actions in the kidney: evidence for sex differences. Br J Pharmacol 2012;Feb 28. doi: 10.1111/j.1476-5381.2012.01922.x. [Epub ahead of print].
50. Ensling M., Steinmann W., Whaley Connell A. Hypoglycemia: a possible link between insulin resistance, metabolic dyslipidemia, and heart and kidney disease (the cardiorenal syndrome). Cardiorenal Med 2011;1(1):67–74.
51. Strazzullo P., Barba G., Vuotto P. Past history of nephrolithiasis and incidence of hypertension in men: a reappraisal based on the results of the Olivetti Prospective Heart Study. Nephrol Dial Transplant 2001;16:2232–5.
52. Dedov I.I., Mel'nichenko G.A., Fadeev V.V. Endokrinologiya. M.: Meditsina, 2000. 631 s.
53. Kalinchenko S.Yu. Shag vpered v lechenii giperprolaktinemii. M.: Prakticheskaya meditsina, 2010. 94 s.
54. Mel'nichenko G.A., Marova E.I., Dzeranova L.K., Vaks V.V. Giperprolaktinemiya u zhenshchin i muzhchin. M.: Endokrinologicheskii nauchnyi tsentr, 2007. 53 s.
55. Crambert S., Sjöberg A., Eklöf A.C. et al. Prolactin and dopamine 1-like receptor interaction in renal proximal tubular cells. Am J Physiol Renal Physiol 2010; 299(1):49–54.
56. Niemczyk S., Matuszkiewicz-Rowińska J., Szamotulska K. et al. Circadian profile of the prolactin concentration in the patients with end-stage renal failure. Pol Arch Med Wewn 2006;116(6):1137–43.
57. Sari F., Sari R., Ozdem S. et al. Serum prolactin and macroprolactin levels in diabetic nephropathy. Clin Nephrol 2012;78(1):33–9.
58. Carrero J.J., Kyriazis J., Sonmez A. et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012;7(2):207–15.
59. Johansen K.L. Treatment of hypogonadism in men with chronic kidney disease. Adv Chronic Kidney Dis 2004;11(4):348–56.
60. Johansen K.L. Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Semin Dial 2004;17(3):202–8.
